First-in-Human trial seeks safe dose for powerful new lymphoma combo
NCT ID NCT05270057
Summary
This early-stage trial aims to find a safe and tolerable dose of a new drug, loncastuximab tesirine, when combined with a standard chemotherapy regimen (DA-EPOCH-R). It is for adults with aggressive types of B-cell lymphoma, including Burkitt lymphoma, who have not yet received multi-drug chemotherapy. The main goal is to determine the highest dose patients can handle without severe side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
University of Texas Southwestern
Dallas, Texas, 75390, United States
-
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin, 53705, United States
Conditions
Explore the condition pages connected to this study.